ArticleJournal of substance abuse treatment2009
Factors affecting willingness to provide buprenorphine treatment.
Article in Journal of substance abuse treatment, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04650386 (Enhancing Office-based Buprenorphine Treatment), which is not on this map. Cited by 89 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Enhancing Office-based Buprenorphine Treatment: An Adaptive Psychosocial Approach
Who cites it
89 citing papers in PubMed, 4 syntheses or guidelines pooled it, 182 citations in OpenAlex.
- Physician Reluctance to Intervene in Addiction: A Systematic Review.JAMA network open · 2024Pooled it
- Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review.The International journal on drug policy · 2024Pooled it
- Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.JAMA pediatrics · 2022Pooled it
- Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.BMC health services research · 2021Pooled it
- Adoption of Emergency Department-Initiated Buprenorphine for Patients With Opioid Use Disorder: Secondary Analysis of a Cluster Randomized Trial.JAMA network open · 2023Trial
- Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.Journal of substance abuse treatment · 2019Trial
- Randomized pilot trial of Web-based cognitive-behavioral therapy adapted for use in office-based buprenorphine maintenance.Substance abuse · 2019Trial
- A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.The American journal of medicine · 2013Trial
- Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.Addictive behaviors · 2010Trial
- Barriers to Buprenorphine Initiation in Patients Using Fentanyl.JAMA network open · 2026Article
- "There's always somebody that you can identify with": a qualitative study of patient perspectives on buprenorphine group medical visits.Addiction science & clinical practice · 2025Article
- Physician's Attitudes Toward Patients With Opioid Use Disorder and Use of Medications for Opioid Use Disorder Vary by Training.Substance use & addiction journal · 2025Article
- Buprenorphine use among non-hospital residential programs.Drug and alcohol dependence · 2024Article
- Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl.JAMA network open · 2024Article
- Primary care professionals' perspectives on tailoring buprenorphine training for rural practice.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2024Article
- Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims.Drug and alcohol dependence reports · 2023Article
- The potential impact of clinical decision support on nonwaivered primary care clinicians' prescribing of buprenorphine.Health affairs scholar · 2023Article
- Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series.Addiction science & clinical practice · 2023Article
- Design of a pragmatic clinical trial to improve screening and treatment for opioid use disorder in primary care.Contemporary clinical trials · 2023Article
- Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.Drug and alcohol review · 2022Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 1 country.
Funding
Abstract
Buprenorphine is an effective long-term opioid agonist treatment. As the only pharmacological treatment for opioid dependence readily available in office-based settings, buprenorphine may facilitate a historic shift in addiction treatment from treatment facilities to general medical practices. Although many patients have benefited from the availability of buprenorphine in the United States, almost half of current prescribers are addiction specialists suggesting that buprenorphine treatment has not yet fully penetrated general practice settings. We examined factors affecting willingness to offer buprenorphine treatment among physicians with different levels of prescribing experience. Based on their prescribing practices, physicians were classified as experienced, novice, or as a nonprescriber and asked to assess the extent to which a list of factors impacted their prescription of buprenorphine. Several factors affected willingness to prescribe buprenorphine for all physicians: staff training; access to counseling and alternate treatment; visit time; buprenorphine availability; and pain medications concerns. Compared with other physicians, experienced prescribers were less concerned about induction logistics and access to expert consultation, clinical guidelines, and mental health services. They were more concerned with reimbursement. These data provide important insight into physician concerns about buprenorphine and have implications for practice, education, and policy change that may effectively support widespread adoption of buprenorphine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.